Iron poisoning

Summary

Iron poisoning (MONDO:0800385) is a disease and 90 clinical trials. Top therapeutic interventions include deferasirox, deferiprone, and deferoxamine. A subtype of heavy metal poisoning — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 90

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	iron poisoning
Mondo ID	MONDO:0800385
Is cancer (heuristic)	no

Also known as: iron overload · iron toxicity

Disease family

This is a subtype of heavy metal poisoning. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › poisoning › heavy metal poisoning › iron poisoning

Related subtypes (2): thallium poisoning, cesium poisoning

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 90.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	47
PHASE2	17
PHASE4	12
PHASE3	7
PHASE1	4
PHASE2/PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00117507	PHASE4	COMPLETED	Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
NCT00171301	PHASE4	COMPLETED	Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
NCT00654589	PHASE4	COMPLETED	Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload
NCT00800761	PHASE4	COMPLETED	Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
NCT01335035	PHASE4	COMPLETED	Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
NCT01546415	PHASE4	COMPLETED	Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
NCT02041299	PHASE4	TERMINATED	Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias
NCT02443545	PHASE4	TERMINATED	Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
NCT03191201	PHASE4	TERMINATED	A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.
NCT03372083	PHASE4	COMPLETED	Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
NCT03388385	PHASE4	UNKNOWN	Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD
NCT03591575	PHASE4	COMPLETED	Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
NCT00529152	PHASE3	COMPLETED	Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients
NCT00980421	PHASE3	UNKNOWN	Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children
NCT00999349	PHASE2/PHASE3	UNKNOWN	Therapeutic Effects of Silymarin in Patients With B-thalassemia Major
NCT01045525	PHASE3	COMPLETED	Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only in Patients With Dysmetabolic Liversiderosis
NCT01342705	PHASE3	TERMINATED	Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis
NCT01395199	PHASE3	COMPLETED	Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
NCT01825512	PHASE3	COMPLETED	Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
NCT02720536	PHASE3	COMPLETED	Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation
NCT04292314	PHASE2/PHASE3	COMPLETED	Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
NCT00000588	PHASE2	COMPLETED	Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
NCT00000595	PHASE2	COMPLETED	Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
NCT00110266	PHASE2	COMPLETED	Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
NCT00110617	PHASE2	COMPLETED	Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
NCT00138684	PHASE2	COMPLETED	Cytochrome P450 2E1 and Iron Overload
NCT00395629	PHASE1/PHASE2	COMPLETED	Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
NCT00447694	PHASE2	COMPLETED	Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
NCT00602446	PHASE2	TERMINATED	Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
NCT00689182	PHASE2	COMPLETED	Safety and Efficacy of Iron Reduction by Phlebotomy
NCT00901199	PHASE2	COMPLETED	Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
NCT00907283	PHASE2	UNKNOWN	Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
NCT01159067	PHASE2	TERMINATED	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
NCT01740713	PHASE2	COMPLETED	Pharmacokinetic Study of Deferiprone in Paediatric Patients
NCT01927913	PHASE2	WITHDRAWN	Treatment of Iron Overload Requiring Chelation Therapy
NCT02164253	PHASE2	COMPLETED	Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
NCT03801889	PHASE2	WITHDRAWN	SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias
NCT04614779	PHASE2	COMPLETED	Long-term Clinical Study of CN128 in Thalassemia Patients
NCT05355766	PHASE2	COMPLETED	Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients
NCT00004982	PHASE1	COMPLETED	Combination Iron Chelation Therapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEFERASIROX	4	18
DEFERIPRONE	4	12
DEFEROXAMINE	4	8
AMLODIPINE	4	2
FERRIC CARBOXYMALTOSE	4	1
HYDROXYUREA	4	1
NIFEDIPINE	4	1
ARGININE	3	1
HONEY	3	1
SILIBININ	3	1
SILYBIN A	3	1
SP-420	2	3
DEFERITAZOLE	2	1
CHEMBL4635234	0	6
CHEMBL5308485	0	1
SILYBIN B	0	1
SILYMARIN	0	1